Michael Shen

Michael Shen

Titles

Professor, Departments of Medicine, Genetics & Development, Urology, and Systems Biology

Affiliations

Department of Genetics and Development
Department of Systems Biology
Department of Medicine

Michael Shen is a Professor in the Department of Medicine, Genetics and Development, Urology and Systems Biology. His laboratory pursues basic and translational research in the areas of mammalian embryogenesis and stem cell differentiation, as well as development of the prostate gland and molecular mechanisms of prostate tumorigenesis. These studies primarily utilize in vivo analyses involving genetically engineered mice as well as organoid culture methods to investigate molecular pathways, and integrate with systems approaches to elucidate mechanisms of cellular differentiation and cancer.

More News

News

Columbia Team Awarded New Prostate Cancer Grant for Innovative Precision Cancer Research
The Prostate Cancer Foundation (PCF) has announced more than $5.5 million in research funding to six new 2018 PCF Challenge Award teams, including an interdisciplinary team at Columbia University Irving Medical Center. The Columbia team includes Systems Biology faculty Drs. Michael Shen, Andrea Califano and Cory Abate-Shen, with several leading investigators from the Herbert Irving Comprehensive Cancer Center, the James J. Peters Veterans Affairs Medical Center and Dana-Farber Cancer Institute.
Michael Shen Wins Cancer Research Innovation Award
The Bladder Cancer Advocacy Network has awarded Professor Michael Shen, PhD, the 2018 Bladder Cancer Research Innovation Award. The honor singles out scientists whose creative, novel research has great potential to advance therapies for bladder cancer, the fifth most common cancer in the U.S.
Organoids Created from Patients’ Bladder Cancers Could Guide Treatment
A study, led by Professor Michael Shen, published in Cell, details the development of patient-specific bladder cancer organioids that mimic many of the characteristics of actual tumors. The use of organoids may be useful in the future to guide treatment of patients.
Columbia Investigators Awarded New NCI Physical Sciences in Oncology Center
The Center for Topology of Cancer Evolution and Heterogeneity will combine new mathematical approaches and single-cell experimental technologies to study cellular diversity in solid tumors.
Biomarker Identified for Predicting Prostate Cancer Aggressiveness
Measurements of the expression levels of three genes associated with aging can be used to better assess which patients with indolent prostate cancer require treatment.